HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antimicrobial resistance

This article was originally published in The Rose Sheet

Executive Summary

FDA, CDC and NIH will host public meeting Sept. 26 in San Diego, Calif. to solicit comments on development of Public Health Action Plan to Combat Antimicrobial Resistance. Discussion will center on second part of the action plan (global issues). Agencies held a meeting in June to discuss surveillance, prevention and control, research and product development. Evaluation of benefits and risks of antimicrobials in consumer products such as soap were included in action plan unveiled by HHS in 2001 (1"The Rose Sheet" Jan. 22, 2001, In Brief)...

You may also be interested in...

Antimicrobial action plan

Evaluation of benefits/risks of incorporating antimicrobial disinfectants or chemicals into consumer products such as soap included in final interdepartmental antimicrobial resistance action plan unveiled by HHS Jan. 18. Although not specified in the final version, a draft released in June said agencies likely will consider whether such products "have any efficacy in reducing infection" and if they "play a role in promoting drug resistance" (1"The Rose Sheet" June 26, 2000, p. 8). Developed by the Task Force on Antimicrobial Resistance, the plan designates priorities, identifies responsible agencies and creates timelines for facilitating surveillance, prevention and control, research and product development to address antimicrobial resistance. CDC, NIH and FDA are leading task force of 10 agencies and departments

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts